<DOC>
	<DOCNO>NCT03006562</DOCNO>
	<brief_summary>The PREVENTER Trial aim compare use perioperative pharmacologic prophylaxis ( subcutaneous heparin ) intermittent pneumatic compression device ( IPCs ) use IPCs alone prevention venous thromboembolism ( VTE ) radical prostatectomy ( RP ) .</brief_summary>
	<brief_title>PREvention VENous ThromboEmbolism Following Radical Prostatectomy</brief_title>
	<detailed_description>The PREVENTER Trial aim compare use perioperative pharmacologic prophylaxis ( subcutaneous heparin ) intermittent pneumatic compression device ( IPCs ) use IPCs alone prevention venous thromboembolism ( VTE ) radical prostatectomy ( RP ) . Currently , standard practice VTE prophylaxis RP American Urological Association recommend `` pharmacological pneumatic mechanical prophylaxis '' high risk patient . Prior study show 30 % patient United States receive perioperative prophylaxis le 20 % receive pharmacologic agent , compare 98 % patient receive pharmacologic prophylaxis United Kingdom . Some urologist prescribe patient low molecular weight heparin ( LMWH ) discharge 30 day surgery . Additionally , establish risk pharmacologic prophylaxis RP patient , urologist express concern potential impact prophylaxis rate postoperative lymphoceles hematomas . At Johns Hopkins , patient routinely receive pharmacologic VTE prophylaxis perioperative setting RP . Given lack standard practice implication patient safety , investigator propose randomize controlled trial evaluate impact perioperative pharmacologic prophylaxis VTE follow RP hypothesize prevent VTE event without significantly impact rate postoperative bleeding lymphoceles .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Lymphocele</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Men 18100 year age histologically confirm prostate cancer stage undergoing RP Patients would otherwise eligible receive routine postRP care Active treatment VTE Patients judge urologist , primary care doctor , preoperative evaluation center ( PEC ) unsafe forgo pharmacologic prophylaxis systemic anticoagulation postoperatively ( whether systematic anticoagulation indication VTE ) Known adverse reaction heparin ( heparininduced thrombocytopenia allergy ) Epidural analgesia Spinal anesthesia Participation different trial increase patient 's risk VTE</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>